O1‐01‐04: Age‐associated Trajectories of Biomarkers in Early‐onset Alzheimer's Disease, for the Alzheimer's Prevention Initiative
Kewei Chen,Yakeel Quiroz,Laura Jakimovich,Madelyn Gutierrez,Jessica Langbaum,Auttawut Roontiva,Pradeep Thiyyagura,Xiaofen Liu,Wendy Lee,Napatkamon Ayutyanont,Mark Nishimura,Stephanie Parks,Sergio Alvarez,Liliana Lopez,Natalia Acosta-Baena,Anne Fagan,Ken Kosik,Pierre Tariot,Eric Reiman,Francisco Lopera
DOI: https://doi.org/10.1016/j.jalz.2012.05.205
2012-01-01
Abstract:There is growing interest in characterizing and comparing the trajectories of biomarker changes associated with the preclinical stages of AD. Here we capitalize on amyloid PET, CSF, and MRI biomarkers in PS1 e280a mutation carriers and non-carriers from the world's largest known kindred to characterize and compare the cross-sectional age-associated trajectories of fibrillar amyloid accumulation, changes in CSF amyloid and tau levels, and hippocampal volumes in the preclinical and clinical stages of early onset Alzheimer's disease (EOAD). Twenty cognitively normal non-carriers of the PS1 mutation (33.80 ± 8.74years), 19 pre-symptomatic carriers (32.63 ± 8.04 years), and 11 symptomatic carriers (MCI or dementia; MMSE 23.1 ± 3.5; 47.5. ± 5 years), age range 20-56, from the Colombian EOAD kindred were evaluated at a single time point. Florbetapir F18 PET cerebral-to-pontine standardized uptake value ratios (SUVR), normalized hippocampal volumes, and CSF Aβ42 and tau were compared based on mutation status, age, and cognitive performance. Regression curves for trajectories of each biomarker associated with age in PS1-e280a mutation carriers were estimated and compared for linearity, onset of change, and rate of change with age. Compared to non-carriers, carriers had declining hippocampal volumes and CSF Aβ42, and increasing mean cortical florbetapir SUVRs and CSF tau (both total and ptau181) associated with advancing age (P <0.05). Florbetapir amyloid PET showed age-associated change beginning at a mean age of 28 years, 17 years prior to the reported mean age of MCI onset for the Colombian PS1 kindred (45 years), with plateauing levels between ages 37-40 years. Both CSF Aβ42 and tau changes occurred at about age 30, with a higher degree of variability than amyloid PET. Hippocampal volumes diverged between carriers and non-carriers at a mean age of 37 years, 8 years prior to typical clinical onset. Age-associated changes in biomarkers in this EOAD cohort, from data driven models, are similar to hypothesized trajectories of biomarker changes in late onset AD disease progression. Change in amyloid PET and CSF Aβ42 and tau were seen prior to structural imaging changes and clinical symptoms. Longitudinal studies will help determine which biomarkers best predict pre-clinical disease progression and how they can be utilized in preventative treatment trials.